Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 1/2014

01.02.2014 | short review

Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010

verfasst von: Orjana Velikonja, MD, Milica Stefanović, MD, Asst. Lidija Kitanovski, MSc, MD, Assist. prof. Helena Podgornik, PhD, Assist. prof. Janez Jazbec, PhD, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

A review of treatment and survival of children with acute myeloid leukemia (AML) in Slovenia from 1991 to 2010.

Methods

We collected demographic data, information on the time, and course of treatment of patients with AML, which were classified in three risk groups and treated according to standard arm of BFM AML protocols 83, 93, 98, and 04. We assessed the rate of remission, event-free survival and overall survival, the incidence of relapse, the secondary neoplasms, secondary AML, the proportion of patients treated with hematopoietic stem cell transplantation (HSCT) and causes of death. The 2- and 5-year overall survival (5yOS) was estimated according to age group, risk group, the presence of remission, and the time of the treatment.

Results

There were 50 patients, 18 males (36 %) and 32 females (64 %) included in this study. Secondary AML was presented in four patients. Patients treated with HSCT were 18 (36 %), 9 of them in first remission. The 2-year overall survival (2yOS) was 63.7 ± 6.8 % and 5-year survival was 55.0 ± 7.2 %. Differences in survival between age groups (0–5 years, 6–10 years and more than 10 years) was not significant. All patients in standard risk group lived for more than 2 years, in high-risk group 2yOS was 56.7 ± 7.7 % (p = 0.05). Patients who were in remission before second treatment block had 2yOS 77.8 ± 7.4 % and 5yOS 63.8 ± 8.8 %, compared to the patients who were not in remission (2yOSand 5yOS 37.5 ± 12.1 %, p = 0.001). The 2yOS in patients treated with HSCT in first remission was 62 %. There were 17 patients (34 %) who had relapse of the disease, 23 (64 %) patients died, 14 (61 %) due to progression of the disease.

Conclusions

The results of treatment of AML in our center are comparable with other European centers. Survival was better in the standard risk group and in patients who were in remission before second treatment block. We observed a trend of improvement in survival in the time observed.
Literatur
1.
Zurück zum Zitat Ching-Hong P. Childhood leukemias. Cambridge University Press; 2006. Ching-Hong P. Childhood leukemias. Cambridge University Press; 2006.
2.
Zurück zum Zitat World health organization—Europe. Incidence of childhood leukemia. Fact sheet 4.1, December 2009, Code: RPG4_Rad_E1. World health organization—Europe. Incidence of childhood leukemia. Fact sheet 4.1, December 2009, Code: RPG4_Rad_E1.
3.
Zurück zum Zitat Avcin S, Prelog T, Kavcic M, Kitanovski L, Anzic J, Benedik Dolnicar M, Rajic V, Zadravec Zaletel L, Debeljak M, Jazbec J. History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia. MEMO. 2011;4:178–83.CrossRef Avcin S, Prelog T, Kavcic M, Kitanovski L, Anzic J, Benedik Dolnicar M, Rajic V, Zadravec Zaletel L, Debeljak M, Jazbec J. History of treatment and long-term outcome of childhood acute lymphoblastic leukemia in Slovenia. MEMO. 2011;4:178–83.CrossRef
4.
Zurück zum Zitat Tsukimoto I, Tawa A, Horibe K, Tabuchi K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 Trial From the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.PubMedCrossRef Tsukimoto I, Tawa A, Horibe K, Tabuchi K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 Trial From the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–13.PubMedCrossRef
5.
Zurück zum Zitat Reinhardt D. Kooperative AML-BFM Therapiestudien [Internet]. Hannover: Medizinische Hochschule Hannover, Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie/ Onkologie; c 2005–2013 [cited 2013 May 7]. Available at: http://aml.mh-hannover.de/ Reinhardt D. Kooperative AML-BFM Therapiestudien [Internet]. Hannover: Medizinische Hochschule Hannover, Klinik und Poliklinik für Kinderheilkunde, Pädiatrische Hämatologie/ Onkologie; c 2005–2013 [cited 2013 May 7]. Available at: http://​aml.​mh-hannover.​de/​
6.
Zurück zum Zitat Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 46:565–9. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. Pediatr Blood Cancer. 46:565–9.
7.
Zurück zum Zitat Rubnitz J, Gibson B, Smith F. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24:35–63.PubMedCrossRef Rubnitz J, Gibson B, Smith F. Acute myeloid leukemia. Hematol Oncol Clin North Am. 2010;24:35–63.PubMedCrossRef
8.
Zurück zum Zitat Smith M, Gloeckler Ries L, Gurney J, Ross J. Leukemia. SEER Pediatric Monograph, National Cancer Institute: 17–34. Smith M, Gloeckler Ries L, Gurney J, Ross J. Leukemia. SEER Pediatric Monograph, National Cancer Institute: 17–34.
9.
Zurück zum Zitat Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495–502PubMedCrossRef Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106(11):2495–502PubMedCrossRef
10.
Zurück zum Zitat Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677–84.PubMedCrossRef Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677–84.PubMedCrossRef
11.
Zurück zum Zitat Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112:562–71.PubMedCrossRef Creutzig U, Büchner T, Sauerland MC, Zimmermann M, Reinhardt D, Döhner H, et al. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer. 2008;112:562–71.PubMedCrossRef
12.
Zurück zum Zitat Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Torsten H. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082–90.PubMed Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Torsten H. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082–90.PubMed
13.
Zurück zum Zitat Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256–61.PubMedCrossRef Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256–61.PubMedCrossRef
14.
Zurück zum Zitat Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002;100:427–34.PubMedCrossRef Barnard DR, Lange B, Alonzo TA, Buckley J, Kobrinsky JN, Gold S, et al. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation. Blood. 2002;100:427–34.PubMedCrossRef
15.
Zurück zum Zitat Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer. 2005;44:1–7 (Commentary).PubMedCrossRef Ravindranath Y. Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer. 2005;44:1–7 (Commentary).PubMedCrossRef
16.
Zurück zum Zitat Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185–95.PubMedCrossRef Hasle H, Niemeyer CM. Advances in the prognostication and management of advanced MDS in children. Br J Haematol. 2011;154:185–95.PubMedCrossRef
17.
Zurück zum Zitat Tilak V, Sookmane DD, Gupta V, Shukla J. Myelodysplastic syndrome. Indian J Pediatr. 2008;75(7):729–32.PubMedCrossRef Tilak V, Sookmane DD, Gupta V, Shukla J. Myelodysplastic syndrome. Indian J Pediatr. 2008;75(7):729–32.PubMedCrossRef
18.
Zurück zum Zitat Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–15.PubMedCrossRef Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–15.PubMedCrossRef
19.
Zurück zum Zitat Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030–42.PubMedCrossRef Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030–42.PubMedCrossRef
20.
Zurück zum Zitat Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499–506.PubMedCrossRef
21.
Zurück zum Zitat Kern W, Haferlach T, Schoch C, Löffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Kern W, Haferlach T, Schoch C, Löffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
22.
Zurück zum Zitat Niewerth D, Creutzig C, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205–14.PubMedCrossRef Niewerth D, Creutzig C, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116:2205–14.PubMedCrossRef
23.
Zurück zum Zitat Mlakar U. Treatment of acute myeloid leukemia in adults in the period 2008–2011 at the university medical centre Ljubljana. Zdr.Vest. 2012;Supp. II:21–6. Mlakar U. Treatment of acute myeloid leukemia in adults in the period 2008–2011 at the university medical centre Ljubljana. Zdr.Vest. 2012;Supp. II:21–6.
24.
Zurück zum Zitat Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRef Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom medical research council treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674–81.PubMedCrossRef
25.
Zurück zum Zitat Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumors of hematopoietic and lymphoid tissues, 4th Edn. Geneva: WHO Press; 2008. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumors of hematopoietic and lymphoid tissues, 4th Edn. Geneva: WHO Press; 2008.
Metadaten
Titel
Development of treatment and clinical results in childhood acute myeloid leukemia in Slovenia in the period from 1991 to 2010
verfasst von
Orjana Velikonja, MD
Milica Stefanović, MD
Asst. Lidija Kitanovski, MSc, MD
Assist. prof. Helena Podgornik, PhD
Assist. prof. Janez Jazbec, PhD, MD
Publikationsdatum
01.02.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0090-z

Weitere Artikel der Ausgabe 1/2014

memo - Magazine of European Medical Oncology 1/2014 Zur Ausgabe